Comparative Pharmacology
Head-to-head clinical analysis: HIPPUTOPE versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPUTOPE versus MPI DMSA KIDNEY REAGENT.
HIPPUTOPE vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPUTOPE is a diagnostic agent used to assess renal function. It is a radiolabeled compound that undergoes glomerular filtration and tubular secretion, allowing measurement of renal plasma flow and tubular function via imaging.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
100-300 microcuries (3.7-11.1 MBq) intravenous, single dose for renal imaging.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours; prolonged to 6–12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Primarily renal excretion (approximately 90% as unchanged drug via glomerular filtration), with minor biliary/fecal elimination (<10%).
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical